@RheumNow WIN Nutrition session at #EULAR2026 (3) 6.🍟 High UPF intake → increased RA risk (HR 1.06/SD), partly mediated by CRP. Not all NOVA-4 foods are equal 7.💊 Vit D supplementation significantly reduces SLE disease activity — MA of 10 RCTs, SMD −0.54 (p<0.00001). @RheumNow

WIN Nutrition session at #EULAR2026 (2) 🐟 n-3 PUFAs reduce RA risk by 9–10% per SD increase — especially in genetically high-risk individuals. 🫒 Mediterranean diet reduces RA risk by 25% (HR 0.75) & SLE risk by 39% (HR 0.61) in UK Biobank studies. @RheumNow

WIN Nutrition session at #EULAR2026 (1) 🫐Higher fruit intake → RR 0.88 & cereal intake → RR 0.87 for RA onset 🥩 Highest quartile of red & processed meat intake → nearly DOUBLE the risk of RA onset (OR 1.92, CI 1.11–3.35) @rheumnow https://t.co/RhO08FXtLI

• https://x.com/Nellziade/status/2062496633867165972/photo/1

COMPARE Ph I trial CD19 CAR T-cell ACPA+ refractory RA 6 pts median 6.5 b/tsDMARDs Single CAR T infusion after lymphodepletion Safety -CRS only grade 1–2 (no severe events) -No ICANS -Transient neutropenia -No unexpected toxicities Efficacy DAS28-CRP ↓ ~41% median 50% achieved https://t.co/cdEfGKcJUp

• https://x.com/AurelieRheumo/status/2062491277191438681/photo/1

D2T RA shows a linked brain–psychology–immune signature Cohort D2T RA vs non-D2T RA vs HC 91% D2T RA Higher catastrophizing Higher pain sensitivity More emotion-focused coping strategies “Chronic pain-like” profile Associated with higher CNS related gene expression NRG1 https://t.co/nkQco73vqI

• https://x.com/AurelieRheumo/status/2062489005208334506/photo/1

Impt pts to consider in D2T CLE by Prof Wittmann: If tx is not working, ask yourself: is the dx correct? adherence? Main message: treat early When damage is present, tx doesn’t really provide considerable improvements Future drxns? Endotype-directed tx @Rheumnow #EULAR2026 https://t.co/hB48aD7jx5

• https://x.com/RHEUMarampa/status/2062483851641819613/photo/1
• https://x.com/RHEUMarampa/status/2062483851641819613/photo/1

Catching your breath session at #EULAR2026 RA-ILD is heterogeneous, maybe under-recognized and risk stratification remains a challenge (Pierre-Antoine -Jugr) Screening for RA-ILD is only as good as availability of early intervention and treatment (Jeff Sparks) @RheumNow https://t.co/V1JXM3i9wP

• https://x.com/JihaRheum/status/2062481502466682912/photo/1
• https://x.com/JihaRheum/status/2062481502466682912/photo/1
• https://x.com/JihaRheum/status/2062481502466682912/photo/1
• https://x.com/JihaRheum/status/2062481502466682912/photo/1

Catching up with the “Optimising care in SpA” at #EULAR2026 #OP0234 Phase 3 OLINGUITO trial showed filgotinib significantly improved ASAS40 responses vs PBO in both radiographic and non-radiographic axSpA by Week 16, with responses maintained through Week 52. @RheumNow #EULARBest https://t.co/axn6Zv52RA

• https://x.com/DrMiniDey/status/2062474451246318046/photo/1

What to use in #RA #IL6i v #abatacept post #TNFi-IR? H2H #TCZ v #Abatacept Same on primary outcome #CDAI change wk26 BUT If #monoRx TCZ better Better retention #TCZ So you decide which is better! Equal v some advantages w #tocilizumab #EULAR2026 @RheumNow @eular_org #OP0205 https://t.co/xdOx4kQCTC

• https://x.com/Janetbirdope/status/2062462900006953077/photo/1
• https://x.com/Janetbirdope/status/2062462900006953077/photo/1

Leflunomide is not associated w/ incident or progressive ILD Longitudinal CT Study 184 RA pts LEF exposure inversely asso w/ new lung involvement #POS062 #EULAR2026 @RheumNow https://t.co/LBrfycalLf

• https://x.com/AurelieRheumo/status/2062461954145309092/photo/1
• https://x.com/AurelieRheumo/status/2062461954145309092/photo/1

SCOOT study oral split-dose vs SC MTX RA Primary outcome EULAR mod/good response wk16 Non-inferiority NOT met EULAR good response lower with oral split-dose OR 0.53 ACR50 lower with oral split-dose OR 0.51 Safety oral split-dose Higher transaminitis (>2× ULN) 3 serious AEs https://t.co/c8etFKtGwo

• https://x.com/AurelieRheumo/status/2062458795347869778/photo/1
• https://x.com/AurelieRheumo/status/2062458795347869778/photo/1

#EULAR2026 OP Are we closer to controlled trials of CAR-T? Miv-cel KYV-101 autologous CD19 CAR-T reported efficacy and safety profile in 6 patients with severe refractory #RA (median prior bDMARDs: 6) in Phase I COMPARE. Will proceed to Phase II with RTX as a comparator @RheumNow https://t.co/Rb4BFgBDZE

• https://x.com/Yuz6Yusof/status/2062458622936760812/photo/1

TCZ vs ABA head-to-head in #RA after 1-2 prior b/tsDMARDs: SUNSTAR RCT (n=224) didn't hit its primary endpoint (CDAI change at wk 26, p=0.11). But composite response (treatment persistence + LDA + steroid-sparing) favored TCZ: 50.5% vs 35% (p=0.034). @RheumNow #EULAR2026 OP0205

MTX PO split dose MTX (15mg AM + 10mg PM) vs SC in early seropositive #RA in SCOOT RCT (n=252): SC MTX had better EULAR response at 16 wks (OR 0.55, p=0.049) and ↑ transaminitis with oral split. SC MTX remains the preferred route above 15mg/wk. @RheumNow #EULAR2026 OP0206

RENOIR Ph2b pathogenic T-cell depletion rosnilimab RA -Primary endpoint DAS28-CRP change wk12 -2.06 to -2.12 (all doses) vs -1.69 PBO p<0.01 -ACR20/50/70 + CDAI LDA all improved vs PBO -hsCRP reduction across all dose arms -69% CDAI LDA by wk14 -wk 28 extension shows https://t.co/AMfmSded0D

• https://x.com/AurelieRheumo/status/2062456064033906821/photo/1